Joel Hurwitz

Oliver said Asia is primarily an AUM/retirement business, with growing FAS 60 and yen products (over 50% of sales) lifting PFO growth.

Tadros said the PFML run-in effect is behind them, disability incidence and recoveries are favorable, and dental seasonality points to a better H2 nonmedical health ratio.

Ramy cited improved broad-based persistency, rate actions meeting expectations, strong core and voluntary sales, and double-digit voluntary product growth from re-enrollment strategy.

John detailed the 1 MIM integration approach, proactive client/consultant outreach, and well-diversified pipeline. PineBridge added international footprint with 50% AUM outside U.S.

Lyndon Oliver confirmed Q4 surrenders slightly higher due to yen depreciation but full year 2025 surrenders below 2024 levels. 2026 guidance assumes surrenders return to long-term assumption.

Ramy Tadros explained MetLife entered US retail annuity market as institutional reinsurer, leveraging balance sheet strength, investment capability, and capital flexibility. Two flow reinsurance partnerships established within a year, adding to liability origination growth.

John McCallion noted muted H1 from market volatility and PineBridge announcement, but strong H2 flows. Over $630B total AUM with $200B+ third-party. Team working hard to educate external market ahead of standalone segment reporting next year.

John McCallion confirmed very modest $2M post-tax LTC assumption change with ADE in line with expectations. Ramy Tadros noted engagement on risk transfer opportunities but emphasized discipline, book is well managed, well capitalized, well reserved with successful rate action program. Price must be accretive to shareholder value.

Eric Clurfain provided comprehensive overview: largest life insurer in LatAm serving ~30M customers across 6 markets. Fastest-growing channel is third-party distribution through 100+ partners. Accelerator embedded insurance platform has issued ~$300M PFO and serves 5M customers since launch.

Ramy Tadros described competitive but rational market. Regional business particularly important contributor to 9% YTD sales growth given slower jumbo year. Competes on capabilities, experience, and broker relationships beyond price.

Lyndon Oliver reported Asia sales up 10% overall. Japan seeing sequential FX product momentum with new single premium life product well received. Rest of Asia up 41% driven by new China bank partners and strong Korea face-to-face channels.

Ramy Tadros confirmed dental in line with expectations after 1/1 repricing actions. Disability incidents on target with strong recoveries slightly ahead of expectations. Minor headwind from social security administration approval delays. Full year expected at midpoint of range.

Amy detailed broad-based underwriting gains, disability driven by lower incidence, group life by lower frequency, guiding SBD below the range.

Deanna declined to comment on rumors, reiterated a high M&A bar and no interest in scale-only deals requiring a premium.

Joel quantified Chile annuity at $65M revenue and $30M pretax earnings, expected Q3 2026 close. All divestiture impacts fully reflected in 2026 outlook. Capital from Chile to fund elevated buybacks and organic investment. Deanna confirmed legacy life divestiture not a top priority currently.

Joel confirmed accretion post-close through redeployment of freed capital into elevated buybacks and higher-return organic opportunities. Capital deployment plan in 2026 takes this into account.

Joel confirmed $350M buybacks in first half, $225M in Q3, with Q4 expected even further elevated. Strong free capital flow conversion while still investing in business. Deanna emphasized balanced and disciplined approach delivering consistent growing returns over time.

Amy highlighted earnings up 28%, margins expanding 330bp as the intended tradeoff with slower growth. Seeing more attractive opportunities at 1/1 and winning against bids. Technology investments bearing fruit in late 2025 and into 2026. Moving closer to low end of guided range.

Amy acknowledged full-year premium growth will fall short of 6-9% guided range but expects improvement in second half. Brokers seeing higher competitor dental renewals are turning back to Principal bundle. Overall loss ratio at low end supports attractive bundled pricing.

Deanna confirmed Post AUM is larger than past divestitures but earnings impact immaterial. Kamal explained Post overlapped with strong existing high yield capability in PGFI. No impact to medium-term asset management revenue growth or pretax margin targets. Expected to close by end of 2025.

Joel cited examples: delayed hiring, consulting spend, certain travel. Demonstrated by 40bp margin improvement. Committed to responsibly aligning expense with revenue.

Joel provided detailed macro sensitivity framework, noted expense management actions underway. Acknowledged uncertainty but maintained guidance path exists.

Kamal cited 32% increase in CRE equity transactions and nearly $1.9B of private capital deployed in Q4. Joel confirmed VII expected to improve in 2025 with real estate weighted to H2.

Chris gave very detailed breakdown: record WSRS retention, lower participant withdrawal rate, VA lapse to RILA conversion dynamics. Flagged 1 large Q1 outflow of $2.3B.

Yoshizumi said Tsumitasu attracts younger, asset-accumulating customers and that concurrent cancer and medical sales are now well above the initially planned 25%.

Max Broden said Japan inflation near 3% plus a shrinking revenue base makes expense management harder, yet the team lowered the expense ratio, with Morimoto flagging Middle East energy risk.

Max disclosed mid-single-digit millions negative Q1 impact, expected to persist for a couple quarters then approach zero as policies reach paid-up status.

Virgil directly denied any material regulatory pressure beyond the one reported state incident, expressing confidence in forward outlook.

Max attributed USP decline from 30 to 18 points directly to higher yen interest rates reducing the parameter's impact.

Virgil detailed buy-to-build as 20% of $1.6B total US sales. Life/disability up 11.3%, network dental up 48.8%, direct-to-consumer up 10.5%. Earned premium growth of 4% in Q4 and 2.9-3% for year.

Yoshizumi detailed Miraito's unique features including flexible design, children's plans, and premium waiver. Confirmed Tsumitasu showing solid growth from September repricing. Dan added he visited 29 regional banks and 4 shinkin banks, noting over 50% of Tsumitasu buyers are in 30s-40s vs 40% target.

Virgil attributed individual product pressure to broker shift toward group products but highlighted 8% conversion increase, 16% productivity gain, 24% lab growth, 40% dental growth for 9 months, and winning state of Maine PFML contract.

Max clearly explained floating rate income headwind from SOFR cuts and interest rate swap dynamics affecting NII outlook.

Virgil gave comprehensive answer citing tough Q4 2023 comp, deliberate underwriting discipline, and dental platform recovery challenges. Transparent about 33% dental decline.

Del Frias detailed POJ costs of $105M this quarter (down from $130M in Q1), ~$70M related to LP compensation with better-than-expected surrenders, but said it was premature to lower the $525-575M full-year range because impacts are non-linear and compound.

Sullivan defended Group as a highly cash-generative, capital-light business growing low single digits, citing accelerated Premier segment growth and diversification into disability, absence and supplemental health as evidence of down-market traction.

Sullivan attributed lower Life Consultant sales to intentional incentive program changes for efficiency, not POJ-related issues. Does not expect longer-term growth inhibition.

Del Frias referenced $135M restructuring charge yielding $150M run-rate savings in 2027, separate from ongoing investment benefits. Did not quantify investment-driven benefits specifically.

Yanela cited multiple cash flow sources: POJ, Gibraltar, PGFL, PICA (reinsured U.S. dollar business), and Gibraltar Re in Bermuda. Not overly reliant on any single vehicle. No expected impact to capital deployment plans or shareholder distributions.

Andy said no litigation impact through Q1 but expects 2025 market size to normalize from robust 2024 due to macro volatility. Cited $3 trillion in untransacted pension assets and 105% funded status as long-term tailwinds.

Yanela walked through three offsets masking $25M spread benefit: $50M annual expense reallocation, lower spread income on cash from 100bp short-term rate reduction, and accounting methodology refinement reclassifying derivatives from operating to non-operating.

Kalmbach put the Evri underwriting loss at roughly $10 million first half ($7 million in Q2), with only $3-4 million expected in the back half, implying about a 2-point full-year UA margin drag.

Darden attributed soft AIL life sales to agent count rather than the economy, citing rising per-sale premiums as a sign of consumer health and Q2 sequential agent growth.

Yes, 2026 guidance assumes continued favorable mortality generating remeasurement gains vs newly-set assumptions. Focus on obligation ratios and normalized margins (41%+) rather than raw remeasurement dollar amounts.

Prior $500-600M was post-dividend (for buybacks only); $600-700M is total excess FCF. Apples-to-apples is consistent (~$515-615M after $85M dividends). Sustainable from improving mortality, health margins, and favorable investment yields.